At this point in time, the only possibility of curing prostate cancer is through the early detection and treatment of localized disease. The large number of treatment options available for localized prostate cancer, including radical prostatectomy, radiotherapy (either external beam or interstitial), hormone therapy and watchful waiting, can be confusing for the patient. These treatments are associated with different adverse effects, further complicating the treatment decision. As there will inevitably be a trade-off between expected cure and acceptable adverse effects, it is important to discuss all options with the patient. The doctor and patient must together decide the appropriate treatment for him and his tumor.
Introduction
Prostate cancer is the second leading cause of cancer death in the Western world. In the USA, it is estimated that 189 000 new cases of prostate cancer will be diagnosed in 2002 and that 30 200 men will die from the disease. 1 At present, the only possibility for achieving a significant reduction in prostate cancer mortality is through the early detection and treatment of localized disease. Prostate-specific antigen (PSA) screening, improved diagnostic techniques and increased awareness, have led to prostate cancer being diagnosed at an earlier stage of the disease than in the past, 2, 3 with recent data indicating that nearly 80% of prostate cancers in the US are clinically localized at diagnosis. 4 This paper discusses the current treatment options for localized prostate cancer and presents a global consensus on the treatment of localized disease, reached at the recent PROstart workshop, held in Marbella, Spain in April 2002.
Management of localized prostate cancer: the current situation
Although prostate cancer is being detected at an earlier stage than previously, which facilitates the treatment of localized disease, difficulty still remains in determining whether the tumor is truly organ-confined. Up to 50% of men with clinically staged, localized prostate cancer are found to have more advanced disease on pathological examination. 5 -8 Reasons for this may include the poor reliability of digital rectal examination and the low sensitivity and specificity of imaging techniques. The best predictors of localized disease are a low Gleason score at biopsy and a low pre-treatment PSA level 9 in clinically asymptomatic patients.
The range of treatment options for localized prostate cancer is extensive ( Table 1) . The standard therapies with curative intent are radical prostatectomy, either by the open retropubic, perineal or laparoscopic approach, and external-beam radiotherapy. Overall, the outcome following either treatment approach is favorable, with 10 y disease-specific survival rates of 90% and overall survival rates of 75% at 10 y. 10, 11 However, a significant proportion of men (approximately 17 -35%) subsequently face disease progression following either surgery or radiotherapy and require further treatment. 12, 13 This is either due to improper staging (tumors were not actually localized when treated) or much less often to inappropriate or suboptimal treatment. Moreover, significant morbidity is associated with the currently available therapeutic options. A number of new treatment approaches are being developed to improve the outcome for patients with early prostate cancer, including brachytherapy, cryotherapy and high-intensity focused ultrasound.
A further treatment option for localized prostate cancer is hormone therapy, given either before (neoadjuvant) and/or in addition (adjuvant) to treatment of curative intent. The use of hormone therapy as neoadjuvant to radiotherapy has been shown to be beneficial for externalbeam radiotherapy and brachytherapy. In contrast, in the surgical setting, there is no evidence from randomized trials to suggest that neoadjuvant hormone therapy offers any advantage over surgery alone in terms of reduced risk of disease progression and survival, although data from randomized trials have shown that neoadjuvant hormone therapy prior to radical prostatectomy may decrease tumor volume as well as reducing rates of detectable positive surgical margins and extracapsular penetration. This may be due to the inadequate duration of neoadjuvant treatment used in these trials: the 3-month regimens used may possibly have been too short compared with the 8 months required to obtain PSA nadir. Long-term follow-up in large prospective randomized trials will allow definitive conclusions to be drawn with regard to this approach.
First data from the largest clinical trial program to date in the treatment of prostate cancer, the bicalutamide ('Casodex' { ) Early Prostate Cancer (EPC) program, have supported the use of hormone therapy for localized disease. 14 Immediate treatment with the non-steroidal antiandrogen, bicalutamide 150 mg, either alone or as adjuvant to radical prostatectomy or radiotherapy, significantly reduced the risk of objective disease progression irrespective of disease stage (localized or locally advanced) 15 or prior therapy (radical prostatectomy, radiotherapy, or watchful waiting). 16 The trial program is ongoing and further data are awaited. Longer follow-up will determine whether the reduced risk of objective disease progression will translate into a survival benefit for these patients.
In addition to these potentially curative treatment options for localized prostate cancer, watchful waiting is an option for men with shorter life expectancies (< 10 y) and/or comorbid conditions, especially those with lowgrade and early-stage tumors. 17 While this option avoids the adverse effects associated with therapy of curative intent, this approach may place patients at a greater risk of disease progression. Indeed, approximately 50% of men enrolled in the Cancer of the Prostate Strategic Urological Research Endeavour (CaPSURE) who elected watchful waiting required initiation of treatment within 5 y of diagnosis. 18 The reasons why patients required secondary treatment were not assessed; however patients with a higher serum PSA level at diagnosis, those who were younger at diagnosis, and those in whom serum PSA level had changed with time, were more likely to have received secondary treatment. The development of hormone therapies with reduced morbidity, such as the non-steroidal antiandrogens, offers an alternative to watchful waiting for patients unsuitable for more radical treatment. Data from the bicalutamide EPC program demonstrate that immediate treatment with bicalutamide 150 mg significantly reduces the risk of objective disease progression in patients who would have otherwise undergone watchful waiting. 14, 16 
Reaching a consensus on treating localized prostate cancer
At the PROstart workshop, urologists, radiotherapists, and medical oncologists from around the world participated in a highly interactive session where the question, 'Which of the available treatment options for localized prostate cancer should be offered to a patient?' was discussed. The international nature of the group was intended to foster understanding of different medical cultures and healthcare systems, and participants shared their opinions, ideas and experiences. The discussion centered on two patient profiles: a 75-y-old, sexually active man with non-aggressive prostate cancer; and a 60-y-old man with more aggressive disease ( Table 2 ). All the available treatment options, including those of curative intent and more conservative approaches, were considered for each patient (Figure 1 ). The factors considered important when coming to a treatment decision were also reviewed.
Patient profile 1
The question here was, 'Does this patient need any therapy?'. This older patient was not currently experiencing any symptoms and wished to retain his sexual potency; he was therefore suitable for a more conservative treatment approach (ie watchful waiting or hormone therapy). However, given his low Gleason score and PSA level, it was likely that the patient had localized disease and so was an ideal candidate for cure. There was considerable debate about the relative merits of each approach (curative vs conservative) for this particular patient, largely reflecting national differences in the treatment of localized disease. Concerns about recommending radical therapy centered on the patient's age and suitability for surgery, his current lack of symptoms, and his desire to retain potency. Those favoring a radical approach stated that achieving a cure and extending life expectancy were paramount; the patient's age was not considered a barrier to treatment of curative intent, given his good health. However, ultimately, the decision of whether to treat lies with the patient. It was agreed that it was essential to present each option to the patient, and discuss them all with him, his partner, and/or family. It was also considered important that the patient should discuss his personal goals for treatment. This was because for some patients, cure from disease is imperative, while for others quality of life and avoidance of adverse effects may take precedence, despite the risk of disease progression. The patient should also be offered the opportunity to Figure 1 Treatment options considered by the group in response to the question, 'Which of the available treatment options for localized prostate cancer should be offered to a patient?'. EBXRT, external-beam radiotherapy; NSAA, non-steroidal antiandrogen. Note: these treatment options were considered by the group and do not necessarily represent the established treatment options for localized prostate cancer.
discuss his treatment options with other clinicians, such as radiotherapists or medical oncologists.
Patient profilen 2
This patient had a more aggressive tumor, and consequently a poorer prognosis than the patient in profile 1. For this younger patient, who was otherwise in good health, the question was one of how to treat the disease rather than whether to treat. The group reviewed in detail the possible treatment options for this patient (radical prostatectomy, radiotherapy or hormone therapy as neoadjuvant/adjuvant to radiotherapy). In coming to a treatment recommendation, the possibility of cure was weighed against the adverse effects associated with each option, the risk of recurrence, and the need for further treatment. In general, the group felt that radical prostatectomy would be most appropriate for this patient, particularly as he was already experiencing symptoms, as this did not rule out further treatment, if required. If his serum PSA level persisted after surgery and bone scans were negative, then the patient would be an ideal candidate for salvage radiotherapy. However, if his serum PSA level increased sharply, or if a bone scan was positive, then hormone therapy would be the most appropriate subsequent treatment. Again it was agreed that it was essential to discuss each treatment option with the patient and his partner and/or family. In this case, there was the chance that the tumor was no longer confined to the prostate and therefore the implications of this should be explained to the patient.
Making treatment recommendations
Although the final treatment decision rests with the patient, the clinician plays an active role in coming to that decision, providing balanced information about all the treatment options and making a treatment recommendation if asked. When making a recommendation, the stage and aggressiveness of the tumor are of prime importance; patients with aggressive tumors generally require more aggressive treatment. When considering treatment of curative intent, the patient's expected survival with, or without, treatment should be taken into account, along with the adverse effects of the treatment and the patient's individual goals. In deciding to recommend hormone therapy alone as part of a more conservative management plan, the cost of treatment (both in financial terms and in terms of adverse effects) and the patient's expected compliance with therapy should be considered. For some patients, such as older men, those without symptoms, and those wishing to avoid the complications of treatment, watchful waiting may be the appropriate choice. However, the patient's need for active treatment should be considered, as some patients find it psychologically distressing not to be actively treated for their prostate cancer.
The consensus views
After a lively debate, during which the group discussed many of the issues surrounding the treatment of localized prostate cancer, the following consensus views were reached:
After discussing all options and reviewing all available information, sufficient time should be allowed for the patient to make a decision on his treatment. Discussion of treatment options (curative vs conservative) should include the patient's partner and other clinicians. The final decision on treatment rests with the patient, but the clinician should make recommendations if asked to do so, taking into account the priorities of the patient and the information available from randomized clinical trials.
Summary
Localized prostate cancer is one of the few curable cancers and after treatment life expectancy is usually the same as it would have been had the patient not had prostate cancer. There is, however, a wide range of treatment options available for localized prostate cancer, which can be confusing for the patient. In addition, all of the treatment options are associated with adverse effects, but these are relatively unimportant when compared with the significant morbidity and mortality associated with other cancers such as lung or rectum cancer. When counseling a patient, it is essential to discuss all options to determine which is best for the patient and his tumor, as there will inevitably be a trade-off between expected cure and acceptable adverse effects. The doctor and patient, in consultation with the patient's partner and/or family, and in possession of all the information, must together decide the appropriate treatment option for the patient.
